We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byCale Ebbs
Modified over 4 years ago
AXINN, VELTROP & HARKRIDER LLP © 2007 | www.avhlaw.com AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here FDA Hearings on the BPCI Act Chad A. Landmon 90 State House Square 1330 Connecticut Ave, N.W. firstname.lastname@example.org@avhlaw.com Hartford, CT 06103Washington, D.C. 20036 February 3, 2011
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Overview BPCI Act FDA Hearings Issues of Contention Going Forward
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Biologics Price Competition and Innovation Act Adds Section (K) to the Public Health Services Act Creates an approval pathway for biosimilars products that share the same known mechanisms of action, conditions of use, and means of administration as the reference product Creates a period of exclusivity for the first biosimilar product to establish interchangeability Creates a 12 year period of exclusivity for new reference products In place of an Orange Book listing, creates a process for exchange of information between the biosimilar applicant and reference product sponsor
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com
FDA Hearings: Topics for Discussion Biosimilarity Interchangeability Patient Safety and Pharmacovigilance Use of Supportive Data and Information Guidances Exclusivity
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Basic Lines of Division InnovatorsBiosimilar Proponents FDA should not start approval until specific and general guidelines are in place Cannot extrapolate across indications Full and robust clinical trials are needed for all indications Approval should be on a case by case basis Extrapolation should be allowed for indications with the same mechanism of action Clinical trials can be abbreviated based on the similarities between the products
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Interchangeability- Innovator View Product is process. Post-market drift and later approved indications means interchangeability can and should be revoked when no longer present. Interchangeability cannot be extrapolated. Interchangeability must be shown for all individuals.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Interchangeability- Biosimilar Proponent View Technology exists to detect differences between products. FDA comparability studies allow drift in the reference product. The same studies should allow interchangeability under the same standards.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Interchangeability- Other Concerns Patient groups stressed patient knowledge and choice and advocated for no automatic substitution. Some proposed a post-market system for approving interchangeability. FDA stressed the worry that drift would result in separately changing products. There may be difficulties in conducting alternating or switching studies, especially for drugs with long half-lives.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Biosimilarity- Innovator View Equivalence rather than noninferiority should be the standard for efficacy. Clinical trials should be conducted across all indications and based on: –complexity of the molecule; –changes introduced during processing and purification; and –immunogenicity risks No surrogate endpoints should be allowed, and no extrapolation across indications.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Biosimilarity- Biosimilar Proponent View Drift in innovator product should establish goal posts for biosimilarity. Clinical trials can and should be abbreviated. Studies should use surrogate endpoints such as efficacy for immunogenicity and response rate for survival. Approval should extrapolate across indications with the same mechanisms of action.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Clinical Trials- Where to Abbreviate? Studies may focus on PK/PD instead of structural similarity since the goal is same efficacy. Non-toxic reference products may allow simultaneous human and animal studies. Clinical studies may be abbreviated based on differences detected between products. Human trials may be abbreviated based on low immunogenicity and general safety.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Pharmacovigilance and Naming Biosimilar proponents argued that tracking can be done through National Drug Codes and lot numbers without unique International Nonproprietary Names. Innovators argued that unique names are required for tracking by patients and doctors. Patient groups stressed that either system needs to deal with patient and doctor confusion. Both sides worried about the effects on insurance reimbursement for their products.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Reliance on Foreign Systems The European Medicines Agency has an established system for biologics. The EMA has high standards for biosimilarity. The EMA has no approval for interchangeability approval is made by individual member states and has yet to be approved by any. Innovators advocated adopting similarly high standards in the U.S. The EMA has no unique naming system, but uses a combination of trade names and INN to identify products.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Innovators pointed to the EMA as having a de facto unique naming system. Innovators supported looking to the EMA for strict standards for approval. Innovators argued that significant bridging data should be required for any reliance on foreign data, even if the only difference in products is the source. Biosimilar proponents supported looking to foreign data with little bridging. Reliance on Foreign Systems
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Exclusivity The BPCIA allows approval of a new 12 year exclusivity period for non-related entities for any structural change that results in a difference in purity, safety or potency. Some pointed out that the provision may conflict with Helsinky rules on replication of clinical trials by forcing duplicative human studies. One presenter noted that clarity is needed on whether after- filing acquisition of the applicant or licensing of the product by the original innovator relinquishes the new exclusivity.
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com Innovators argued that this approval should be granted for any change, not just an improvement. Patient groups expressed worry in evergreening and the incentive to make minor improvements rather than new innovations One innovator requested that products that would qualify as biosimilar should not be able to skirt the 12 year exclusivity of the reference product by seeking approval as a new biologic. Exclusivity
AXINN, VELTROP & HARKRIDER LLP © 2011 | www.avhlaw.com At the hearings, the representative for BIO asked that FDA interpret Sections (a) and (k) of the act as mutually exclusive, so a product that would qualify under the biosimilarity provisions of (k) not be granted approval under (a). Members of both houses of Congress have recently written FDA to emphasize that the exclusivity is data not marketing exclusivity, as the provision does not prohibit or prevent another manufacturer from developing its own data to justify FDA approval. Biosimilar proponents have since written to FDA to point out that the exclusivity provision has two separate periods of exclusivity a four year period preventing filing of an abbreviated application under Section (k) ( data exclusivity ) and a twelve year period before an application can be approved under Section (k) ( marketing exclusivity ). Exclusivity
AXINN, VELTROP & HARKRIDER LLP © 2007 | www.avhlaw.com AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here Any questions? Chad A. Landmon email@example.com (860) 275-8100 (202) 721-5415
Presented by Richard J. Berman, Partner Arent Fox LLP Washington, DC
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Safe Substitution of Biologics. What is automatic substitution? 1) Physician writes a prescription2) Pharmacist is allowed, or required, to provide a.
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
BIOSIMILARS IN THE UNITED STATES – UPDATE ON FDA IMPLEMENTATION AND OTHER CURRENT ISSUES James C. Shehan Hyman, Phelps & McNamara, P.C. 700 Thirteenth.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Biopharmaceutical Regulatory Requirements 1. Marketing Authorization for Chemical Entities MoH Federal Commission for the Protection against Health Risks.
New York Washington Seattle Brian J. Malkin, Partner Brian J. Malkin, Partner Frommer Lawrence.
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
© 2018 SlidePlayer.com Inc. All rights reserved.